Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Global Therapeutic Clinical Trials Review, H2, 2018

GlobalData
423 Pages - GLDATA66242
$2,500.00

Summary

GlobalData's clinical trial report, “Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Global Clinical Trials Review, H2, 2018" provides an overview of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Companies Mentioned
Takeda Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
AbbVie Inc
Johnson & Johnson
Celgene Corp
Amgen Inc
Novartis AG
AstraZeneca Plc
Bayer AG

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 27
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) 40
Jul 17, 2018: Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study 40
Clinical Trial Profile Snapshots 41
Appendix 421
Abbreviations 421
Definitions 421
Research Methodology 422
Secondary Research 422
About GlobalData 422
Contact Us 423
Disclaimer 423
Source 423

List of Tables
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, G7 Countries (%), 2018* 17
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 21
Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, E7 Countries (%), 2018* 23
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 26
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Phase, 2018* 27
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 28
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 30
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 33
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 35
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 37
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 39

List of Figures
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, E7 Countries (%), 2018* 22
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 27
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 28
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 33
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38
GlobalData Methodology 422

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports